Assembly Biosciences (NASDAQ:ASMB – Get Free Report) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Thursday.
Assembly Biosciences Stock Down 0.6 %
Shares of NASDAQ ASMB traded down $0.08 during midday trading on Thursday, reaching $13.30. 30,210 shares of the company were exchanged, compared to its average volume of 29,694. The stock’s 50-day moving average price is $12.10 and its 200-day moving average price is $10.58. The stock has a market cap of $72.88 million, a P/E ratio of -0.78 and a beta of 0.56. Assembly Biosciences has a one year low of $7.69 and a one year high of $20.04.
Insiders Place Their Bets
In other news, major shareholder Alexander Schornstein acquired 24,999 shares of the stock in a transaction dated Wednesday, January 17th. The stock was bought at an average price of $9.36 per share, with a total value of $233,990.64. Following the completion of the purchase, the insider now directly owns 655,357 shares of the company’s stock, valued at approximately $6,134,141.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.10% of the company’s stock.
Institutional Trading of Assembly Biosciences
About Assembly Biosciences
Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.
Featured Articles
- Five stocks we like better than Assembly Biosciences
- Find and Profitably Trade Stocks at 52-Week Lows
- 3 Value Stocks Too Small For Buffett’s Portfolio
- 3 Fintech Stocks With Good 2021 Prospects
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- 3 Tickers Leading a Meme Stock Revival
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.